Abstracts tagged "Early Rheumatoid Arthritis and treatment"

Abstract Number: 2460 • 2016 ACR/ARHP Annual Meeting
Predictive Factors of Good Response to Conventional Dmards in Patients with Early Seronegative Rheumatoid Arthritis: Data from the Espoir Cohort
JULIA MARY¹, B Combe², Cédric Lukas³ and Michel De Bandt⁴, ¹RHEUMATOLOGY, CHU Fort de France, 97261, Martinique, ²Immuno-Rhumatologie, CHU Lapeyronie, University of Montpellier, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology department, CHU Fort de France, Fort de France, France
Background/Purpose: Early seronegative rheumatoid arthritis (RA) is a separate entity. Less is known about its initial clinical presentation and outcome due to the difficulty in…
Abstract Number: 3213 • 2016 ACR/ARHP Annual Meeting
Assessment of Two Different DAS Treatment Targets in Early Active Rheumatoid Arthritis Patients
Gülsah Akdemir¹, Iris M. Markusse², Yvonne P. Goekoop-Ruiterman³, J.B. Harbers⁴, Maikel van Oosterhout⁵, Pit J.S.M. Kerstens⁶, Willem F. Lems⁷, TWJ Huizinga⁸ and Cornelia F. Allaart², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, LUMC, Leiden, Netherlands, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Department of Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, ⁵Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁶Department of Rheumatology, Reade, Amsterdam, Netherlands, ⁷Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ⁸Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: It remains to be determined if setting remission or low disease activity as treatment target affects significant outcomes in early active rheumatoid arthritis (RA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].